Tech Company Financing Transactions
Cortexyme Funding Round
Cortexyme closed a $76 million Series B investment round on 6/1/2018. Investors included Breakout Capital, Dolby Family Ventures and Epiq Capital.
Transaction Overview
Company Name
Announced On
6/1/2018
Transaction Type
Venture Equity
Amount
$76,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.COR388 was found to be safe and well tolerated by healthy volunteers ranging in age from 20-70 years old, producing a favorable pharmacokinetic profile and tissue distribution when given orally in a wide range of doses. Based on these encouraging results, the company is planning to start a phase 2 proof of efficacy study in AD patients next year.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
269 East Grand Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Cortexyme (Nasdaq: CRTX) is developing treatments for Alzheimer's and other degenerative disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Casey Lynch
Chief Scientific Officer
Stephen Dominy
Executive Vice President
Leslie Holsinger
VP - Operations
Kristen Gafric
Browse more venture capital transactions:
Prev: 6/1/2018: Alfred venture capital transaction
Next: 6/1/2018: RideCell venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs